Search research articles
Contact Us
Filters
Showing results (101-110 of 140) with videos related to
Page
of 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)
Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2024
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
Manmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, et al.
Cancer Research Communications
|
August 20, 2024
A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Yasuhiro Arakawa, Fathi Elloumi, Sudhir Varma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 5, 2022
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring <i>CCNE1</i> Amplification
Siqing Fu, Shuyang Yao, Yuan Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2016
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P D'Angelo, Alexander N Shoushtari, Mary Louise Keohan, et al.
Cancer Research Communications
|
March 7, 2024
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts
Yasuhiro Arakawa, Ukhyun Jo, Suresh Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2016
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial
Ran Xu, Fumiko Shimizu, Koos Hovinga, et al.
JCO Precision Oncology
|
September 19, 2024
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)
Margaret E Macy, Rajen Mody, Joel M Reid, et al.
British Journal of Clinical Pharmacology
|
July 5, 2019
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction
Naoko Takebe, Jan H Beumer, Shivaani Kummar, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 140) with videos related to
Sort By:
Page
of 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)
Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2024
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
Manmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, et al.
Cancer Research Communications
|
August 20, 2024
A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Yasuhiro Arakawa, Fathi Elloumi, Sudhir Varma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 5, 2022
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring <i>CCNE1</i> Amplification
Siqing Fu, Shuyang Yao, Yuan Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2016
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P D'Angelo, Alexander N Shoushtari, Mary Louise Keohan, et al.
Cancer Research Communications
|
March 7, 2024
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts
Yasuhiro Arakawa, Ukhyun Jo, Suresh Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2016
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial
Ran Xu, Fumiko Shimizu, Koos Hovinga, et al.
JCO Precision Oncology
|
September 19, 2024
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)
Margaret E Macy, Rajen Mody, Joel M Reid, et al.
British Journal of Clinical Pharmacology
|
July 5, 2019
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction
Naoko Takebe, Jan H Beumer, Shivaani Kummar, et al.
Page
of 14